 BOSTON, July 13, 2021 GLOBE NEWSWIRE -- Imara Inc. the Company Nasdaq: IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the pricing of its previously announced underwritten public offering of shares of its common stock at a public offering price of 6.00 per share, for gross proceeds of 50 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on July 16, 2021, subject to customary closing conditions. All shares are being offered by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to 7.5 million of additional shares of its common stock at the public offering price, less underwriting discounts and commissions. 